{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:12:57Z","timestamp":1790629977460,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202133"],"award-info":[{"award-number":["7202133"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242201"],"award-info":[{"award-number":["7242201"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104052"],"award-info":[{"award-number":["82104052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpha.2026.101550","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:20:36Z","timestamp":1767745236000},"page":"101550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors"],"prefix":"10.1016","volume":"16","author":[{"given":"Dan-Dan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Jun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-5803","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Juan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-741X","authenticated-orcid":false,"given":"Qing-Fang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2026.101550_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.jpha.2026.101550_bib2","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jpha.2026.101550_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30766","article-title":"Children's oncology group's 2023 blueprint for research: surgery","volume":"71","author":"Gow","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jpha.2026.101550_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","article-title":"Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities","volume":"46","author":"Maiti","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jpha.2026.101550_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13244-024-01627-6","article-title":"The use of PET\/MRI in radiotherapy","volume":"15","author":"Yan","year":"2024","journal-title":"Insights Imaging"},{"key":"10.1016\/j.jpha.2026.101550_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12032-023-02168-6","article-title":"Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib7","first-page":"155","article-title":"Targeted cancer therapies","volume":"103","author":"Smith","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jpha.2026.101550_bib8","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/pharmaceutics15041242","article-title":"Advances in targeted therapy of breast cancer with antibody-drug conjugate","volume":"15","author":"Subhan","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpha.2026.101550_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/cancers15061845","article-title":"Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jpha.2026.101550_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212443","article-title":"Host mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment","volume":"22","author":"Hilliard","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpha.2026.101550_bib12","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jpha.2026.101550_bib13","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jpha.2026.101550_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jpha.2026.101550_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925217","article-title":"A novel PD-L1-containing MSLN targeting vaccine for lung cancer immunotherapy","volume":"13","author":"Zeng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpha.2026.101550_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jpha.2026.101550_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting mesothelin in solid tumours: anti-mesothelin antibody and drug conjugates","volume":"25","author":"Chu","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jpha.2026.101550_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41416-021-01658-6","article-title":"Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine","volume":"126","author":"Chen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jpha.2026.101550_bib19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpha.2026.101550_bib20","doi-asserted-by":"crossref","first-page":"15027","DOI":"10.1007\/s00432-023-05279-9","article-title":"Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer","volume":"149","author":"Zhu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/01480545.2021.2005085","article-title":"Preclinical safety profile of RC88-ADC: a novel mesothelin-targeted antibody conjugated with monomethyl auristatin E","volume":"46","author":"Jiang","year":"2023","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.jpha.2026.101550_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-ImmunoPET","volume":"16","author":"Terwisscha van Scheltinga","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.jpha.2026.101550_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in aatients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpha.2026.101550_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib25","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jpha.2026.101550_bib26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3389\/fonc.2019.00861","article-title":"An engineered fusion protein anti-CD19(fab)-LDM effectively inhibits ADR-Resistant B cell lymphoma","volume":"9","author":"Fan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpha.2026.101550_bib28","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpha.2026.101550_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127105","article-title":"Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2","volume":"253","author":"Zhou","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jpha.2026.101550_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2015.1114320","article-title":"The INNs and outs of antibody nonproprietary names","volume":"8","author":"Jones","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.jpha.2026.101550_bib31","doi-asserted-by":"crossref","first-page":"D413","DOI":"10.1093\/nar\/gku1056","article-title":"IMGT\u00ae, the international ImMunoGeneTics information system\u00ae 25 years on","volume":"43","author":"Lefranc","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpha.2026.101550_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10637-013-9995-y","article-title":"Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by ofatumumab conjugated with Auristatin","volume":"32","author":"Li","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jpha.2026.101550_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-024-00584-z","article-title":"A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers","volume":"8","author":"Zhou","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1878-0261.12166","article-title":"A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas","volume":"12","author":"Wang","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6750-13-55","article-title":"Monoclonal antibody humanness score and its applications","volume":"13","author":"Gao","year":"2013","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jpha.2026.101550_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody\u2013drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jpha.2026.101550_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel antibody therapeutics targeting mesothelin in solid tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"key":"10.1016\/j.jpha.2026.101550_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.CCR-11-2701","article-title":"Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpha.2026.101550_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","article-title":"Critical issues in the development of immunotoxins for anticancer therapy","volume":"109","author":"Kim","year":"2020","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2026.101550_bib40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-08-2753","article-title":"C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells","volume":"69","author":"Beerman","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2026.101550_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/jmbi.2001.4621","article-title":"Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore","volume":"309","author":"Tanaka","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jpha.2026.101550_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jpha.2026.101550_bib43","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.jpha.2026.101550_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004704","article-title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies","volume":"10","author":"Pascual-Pasto","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jpha.2026.101550_bib46","first-page":"400","article-title":"Examining the characteristics of colchicine-induced myelosuppression in clinical cases: a systematic review","volume":"50","author":"Sim","year":"2023","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jpha.2026.101550_bib47","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jpha.2026.101550_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpha.2026.101550_bib49","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Therapeut."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177926000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177926000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:17:56Z","timestamp":1786033076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177926000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2095177926000055"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2026.101550","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2026.101550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}],"article-number":"101550"}}